

EXACERBATION PHONE VISIT FORM (BASELINE)

	ID NUMBER: FORM CODE: EPV VERSION: 1.0 03/03/2021 Event:						
0a	Date of Collection: / / / / / / / / / / / Ob) Staff Code: /						
	Istructions: This form should be completed primarily over the phone for the participant's Exacerbation Substudy hone Visit at Baseline. Please note that items 1 and 2 are populated based on the TEA data collection form entry.						
1)	Date of phone contact						
2)	Date symptoms first started / /						
3)) Was the participant able to self-collect samples within seven days of exacerbation event onset?						
	\square No ₀ \longrightarrow End Form						
	□Yes₁						
4)	Are the exacerbation event symptoms ongoing?						
	□ No ₀						
	$\square \text{ Yes}_1 \rightarrow \text{Go to 5}$						
	4a) If No, when did the exacerbation event symptoms stop?						
	4b) Has it been more than 48 hours since the exacerbation event symptoms stopped?						
	\square No ₀						
	Yes₁ → End Form; participant does not meet inclusion criteria for Exacerbation Phone Visit.						
	view of Symptoms						
5)	5) Since the start of your exacerbation event symptoms, have you experienced an increase and/or change in the following <u>major</u> symptoms for at least two or more consecutive days?						
	<u>No₀</u> <u>Yes</u> ₁						
	5a) Shortness of breath						
	5b) Change in sputum discharge color (yellow/green)						
	5c) Sputum volume						

	ID NUMBER:								FORM CODE: EPV VERSION: 1.0 03/03/2021	Event:		
6)		•							symptoms, have you experi- consecutive days?	enced an inc	rease ir <u>No</u> ₀	n the following Yes ₁
	6a) Nasal disc	harg	е									
	6b) Wheeze											
	6c) Sore throa	t										
	6d) Cough											
	6e) Fever											
	Are you able to $\square No_0 \rightarrow \bigcirc Go \text{ to}$	take		tem	npera	atur	e?					
	∐Yes₁ 7a) Tempera	ature) :									o
8)	Are you able to $\square No_0 \rightarrow \bigcirc Go to$ $\square Yes_1$ 8a) Oxygen	9			r oxy	/gei	n sa	atura	ation level?			
	8b) Do you (No ₀ – Yes ₁ 8b1)	→ Go	to 9 is a n						oxygen? xygen therapy?			
	8b2)	Is it a □N □Y	O ₀	crea	se to	о уо	ur	usua	al oxygen therapy?			
De	sacerbation Eve efinition: A proba ajor symptom ar	able e	exace	erba	tion	eve		is de	efined as an increase in <u>two</u>	or more ma	<u>ior</u> sym _l	otoms or <u>one</u>
	Is this a probab No₀ → Go Yes₁ acerbation Phone V	to 10					ba	ased	d on the above definition?		Page 2 (of 5

	ID NUMBER: VERSION: 1.0 03/03/2021 Event:
	9a) If Yes, what is the event duration to date?
	☐ Less than 1 day₁
	☐ 1-2 days₂
	☐ 3-5 days₃
	1 week ₄
	☐ More than 1 week₅
	9b) Suspected cause (etiology)
	☐ Infection ₁
	☐ Weather₂
	☐ Treatment non-compliance₃
	☐ Unknown₄
10	Have you been <u>tested</u> for COVID-19 as part of this illness? No₀→Go to 11 Yes₁ Unsure₂→Go to 11 10a) If Yes, what was the result? Negative₀ Positive₁ Unsure₂ Unsure₂
11) Have you been in contact with anyone with COVID-19 in the last two weeks? No ₀ Yes ₁ Unsure ₂
12	P) Have you been <u>vaccinated</u> against COVID-19? ☐ No ₀ → Go to 13 ☐ Yes ₁ ☐ Unsure ₂ → Go to 13 12a) If Yes, when were you vaccinated: ☐ / ☐ / ☐ ☐ / ☐ ☐
	ample Collection Tracking Sa) Did the participant collect and freeze the self-collected spontaneous sputum sample within seven days or
	exacerbation event onset?
	$\square No_0$
	□Yes ₁

FORM CODE: **EPV**

	ID NUMBER:
L	
13	b) Did the participant collect the nasal swab sample within seven days of exacerbation event onset? \[\Boxed{\text{No}_0} \] \[\Boxed{\text{Yes}_1}
13	c) Did the participant collect the dried blood spot sample within seven days of exacerbation event onset? \[\sum No_0 \] \[\sum Yes_1 \]
	□1 e31
	Accerbation Event Treatment
· 4) Was the participant's clinical treatment or medication(s) changed? ☐ No₀ → Go to 15
	☐ Yes₁
	If Yes, Complete items 14a-14g.
	14a) Antibiotics
	\square No ₀ \rightarrow Go to 14b
	☐ Yes₁
	14a1) If Yes, please specify:
	14a2) Number of days prescribed:
	14b) Oral glucocorticosteroids
	\square No ₀ \rightarrow Go to 14c
	☐ Yes₁
	14b1) Number of days prescribed:
	14c) New inhaled glucocorticosteroid
	\square No ₀ \rightarrow Go to 14d
	☐ Yes₁
	14c1) Number of days prescribed:
	14d) Increased inhaled glucocorticosteroid dosage
	14d1) Number of days prescribed:
	14e) Methylxathines (new)
	\square No ₀ \rightarrow Go to 14f
	☐ Yes₁
	14e1) Number of days prescribed:

ID NUMBER:	FORM CODE: EPV VERSION: 1.0 03/03/2021	Event:								
14f) β_2 -agonists (short-acting) (new or inc \square No ₀ \rightarrow Go to 14g	creased)									
☐ Yes₁										
14f1) Number of days prescribed:										
14g) Other significant clinical treatments	or medications									
☐ Yes₁ 14g1) If Yes, please specify:		-								
14g1a) Number of days prescribe	14g1a) Number of days prescribed:									
14g2) If Yes, please specify:		-								
14g2a) Number of days prescribe	ed:									
14g3) If Yes, please specify:		-								
14g3a) Number of days prescribe	ed:									
14g4) If Yes, please specify:										
14g4a) Number of days prescribe	ed:									
NOTE: The Exacerbation Phone Visit may end if you are unable to communicate with the revie	•	leted and entered at a later time								
Physician Review										
15) Does the reviewing physician suspect any	conditions other than or in addi	tion to Acute Exacerbation								
COPD (AECOPD)?										
\square No ₀ \longrightarrow Go to End										
☐ Yes₁ If Yes, please specify the conditions that	t were ruled out.									
15a) 🗌 Pneumonia										
15b) Acute Respiratory Failure										
15c) ☐ Other 15c1) If Other, please specify:										

END OF FORM